GeneTether Therapeutics, Inc. (TSE:GTTX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GeneTether Therapeutics Inc. has successfully secured shareholder approval for a significant licensing agreement with EGB Ventures for STS-201, a promising cancer treatment. This agreement, along with a fully subscribed private placement raising C$500,000, marks a key milestone for the company’s strategic growth. The funds will bolster GeneTether’s research and development efforts.
For further insights into TSE:GTTX stock, check out TipRanks’ Stock Analysis page.